Giovanni Gaviraghi#

Short laudatio by Theophile Godfraind#

Main skills of Giovanni Gaviraghi stem from his long experience in the industrial research, lasting more than 35 years. He has been involved in many applied research programs, ranging from cardiovascular research (hypertension , atherosclerosis and cardiac ischemia), antiinfectives (beta Iactams, trinems, quinolones) to neurology (neurodegeneration) and psychiatry (depression and schizophrenia) . Most importantly, he has fully participated to the discovery, pharmacological characterization, development, registration and launch of the dihydropyridine calcium channel antagonist lacidipine.

Lacidipine is a potent and long lasting anti hypertensive drug, showing also anti atherosclerotic properties, currently widely used in therapy, Other NCE’s put in the development include a glycine antagonist for the treatment of cerebral stroke, a new type of oral/injectable beta lactam class calle trinems and a CCK2 antagonist for the treatment of anxiety/depression.

Current research interests are focussed in brain disorders, such as neurodegenerative diseases (Alzheimer, Huntington) and neuroproliferative diseases (Glioblastoma Multiforme). He has also developed a wide range of managerial skills, including recruitment, coaching and management of researchers, and budget control, He was also involved in the design and construction of state of the art research facilities such as the GSK Research Centres in Verona and Madrid, and the new Medicines Research Centre of Siena Biotech in Siena. He has held and still holding a number of position in the academia, as adjunct professor of medicinal chemistry, pharmacology and pharmacy.

Any further pages in alphabetic order of their title as created by you.

Just click at "Create new page", then type a short title and click OK, then add information on the empty page presented to you (including maybe a picture from your harddisk or a pdf-file by using the "Upload" Button) and finally click at "Save". Data available yet!

Imprint Privacy policy « This page (revision-4) was last updated on Wednesday, 16. March 2011, 21:15 by Kaiser Dana
  • operated by